Fortrea Holdings (FTRE) Payables (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Payables came in at $54.2 million in Q2 2026, down 41.47% YoY from $92.6 million in Q2 2025, and down 23.45% on a QoQ basis from $70.8 million in Q1 2026.
Fortrea Holdings (FTRE) Payables (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Payables data on file, last reported at $54.2 million in Q2 2026.
- Quarterly Payables fell 41.47% year-over-year to $54.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $54.2 million (down 41.47% YoY) and the FY2025 annual result came in at $29.7 million, down 78.51% from the prior year.
- Payables declined to $54.2 million in Q2 2026, from $70.8 million in the prior quarter.
- In the past five years, Payables ranged from a high of $144.2 million in Q2 2024 to a low of $29.7 million in Q4 2025.
- A 5-year average of $100.4 million and a median of $107.8 million in 2023 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables jumped 63.07% — and 2025, when it sank 78.51%.
- Tracing FTRE's Payables over 5 years: stood at $81.5 million in 2022, then jumped by 63.07% to $132.9 million in 2023, then rose by 3.99% to $138.2 million in 2024, then slumped by 78.51% to $29.7 million in 2025, then soared by 82.49% to $54.2 million in 2026.
- The last three Payables figures came in at $54.2 million (Q2 2026), $70.8 million (Q1 2026), and $29.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 54.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.20 Mn |
| Mar 31, 2026 | 70.80 Mn |
| Dec 31, 2025 | 29.70 Mn |
| Sep 30, 2025 | 49.50 Mn |
| Jun 30, 2025 | 92.60 Mn |
| Mar 31, 2025 | 110.20 Mn |
| Dec 31, 2024 | 138.20 Mn |
| Sep 30, 2024 | 137.60 Mn |
| Jun 30, 2024 | 144.20 Mn |
| Mar 31, 2024 | 131.30 Mn |
| Dec 31, 2023 | 132.90 Mn |
| Sep 30, 2023 | 128.30 Mn |
| Jun 30, 2023 | 105.30 Mn |
| Dec 31, 2022 | 81.50 Mn |